Drugs / Ad5.F35-hGUCY2C-PADRE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07417488 | Apr 2026 → Oct 2027 expected | colorectal cancer, small intestine adenocarcinoma | Thomas Jefferson University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad5.F35-hGUCY2C-PADRE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07417488 ↗ |
| Modality | Vaccine | “Ad5.F35-hGUCY2C-PADRE vaccine administered as a single intramuscular injection at a dose of 5 × 10¹² viral particles as the priming vaccination in a heterologous prime-boost...” NCT07417488 ↗ |
| Route | Intramuscular | “Ad5.F35-hGUCY2C-PADRE vaccine administered as a single intramuscular injection” NCT07417488 ↗ |